Kezar Life Sciences, Inc. · NASDAQ:KZR

Kezar Life Sciences — Technical Presentation (November 2025)

14 slides from Kezar Life Sciences's technical presentation, Nov 10, 2025

  1. Slide 1: Zetomipzomib Demonstrates Steroid Sparing Biochemical Remission in Autoimmune Hepatitis

    Zetomipzomib, a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrates Steroid Sparing Biochemical Remission in Patients with Relapsed or Insufficiently Responding Autoimmune Hepatitis in a Randomized, Double-blind, Placebo-controlled, Phase 2a Study Craig Lammert, MD Associate Professor

  2. Slide 2: Disclosures

    Disclosures • Consultant and Investigator for Kezar Life Sciences • Consultant Amgen, Eli Lilly, RegCell, Mirum • Executive Director, Autoimmune Hepatitis Association Slides are the property of the author and AALSD. Permission is required from both AASLD and the author for reuse. 2

  3. Slide 3: Zetomipzomib Has Potential to Modulate Multiple Immune Pathways Underlying Autoimmune Hepatitis

    Zetomipzomib Has Potential to Modulate Multiple Immune Pathways Underlying Autoimmune Hepatitis Cellular Dysfunction Observed Zetomipzomib Targets Multiple in AIH Immune Effector Cells Involved in Autoimmunity Zetomipzomib Significant Unmet Needs in AIH Treg Treg • Long-term corticosteroids and immu

  4. Slide 4: Treatment Goals Are Focused on Biochemical Normalization and Low Daily Steroid Dose

    Treatment Goals Are Focused on Biochemical Normalization and Low Daily Steroid Dose AASLD1 EASL2 Biochemical Remission ALT, AST, & IgG normalization by ALT, AST, & IgG normalization by Criteria 6 months 6 months Steroid Prednisone 20-40 mg/d with 0.5-1 mg/kg/d prednis(ol)one with Dose taper to ≤5-10

  5. Slide 5: PORTOLA: Evaluate the Safety and Efficacy of Zetomipzomib in Relapsed or Insufficiently Responding AIH

    PORTOLA: Evaluate the Safety and Efficacy of Zetomipzomib in Relapsed or Insufficiently Responding AIH Double-Blind Treatment (24 Weeks) Optional Open-Label Extension (up to 24 Weeks) Adult Randomization Zetomipzomib 60 mg SC QW + Prednisone 20-40 mg/day patients with 2:1 active AIH 1st dose 30 mg Z

  6. Slide 6: PORTOLA: Demographics and Baseline Characteristics

    PORTOLA: Demographics and Baseline Characteristics ITT Population (N=24) Placebo Zetomipzomib Total Placebo Zetomipzomib Total N=8 N=16 N=24 N=8 N=16 N=24 Age, median (min, max), Antibodies 54.0 (26, 72) 59.0 (25, 75) 57.5 (25, 75) years ANA positive, n (%) 6 (75.0) 14 (87.5) 20 (83.3) Female, n (%)

  7. Slide 7: PORTOLA: Demographics and Baseline Characteristics – Cont'd

    PORTOLA: Demographics and Baseline Characteristics – Cont’d ITT Population (N=24) Placebo* Zetomipzomib Total N=8 N=16 N=24 Concomitant medications at baseline* Prednisone (or equivalent)* n (%) 7 (87.5) 16 (100) 23 (95.8) Prednisone (or equivalent)†, dose in mg/day, median (min, max) 20 (20, 20) 20

  8. Slide 8: Zetomipzomib Treatment Induces Steroid-Free Biochemical Remissions

    Zetomipzomib Treatment Induces Steroid-Free Biochemical Remissions Prespecified Subset Analysis (N=21) AASLD and EASL Guidelines Zeto achieves lower steroid doses in relapsed/refractory AIH patients Target Treatment Goals All Complete Responses (CR) CR with Median Corticosteroid Dose Over Time Stero

  9. Slide 9: Histologic Improvement and Remission Are Observed with Zetomipzomib at W24

    Histologic Improvement and Remission Are Observed with Zetomipzomib at W24 Prespecified Subset Analysis (N=21) Histologic Remission Histologic Improvement (mHAI <4) (≥2 points in mHAI) 25 50 Proportion of Patients (%) Proportion of Patients (%) 21% 43% 20 3/14 3/14 40 6/14 15 14% 14% 29% 29% 30 1/7

  10. Slide 10: PORTOLA Patient Journey

    PORTOLA Patient Journey 67 y/o white male, AIH since 2021 (2.8 years), ANA+, normal IgG and receiving MMF 1.5 g/day + Prednisone 20 mg at Baseline PORTOLA Results • Steroid free CR  Ineligible for OLE (Partial Hold) and flared by Week 28 • Histologic Remission • Liver Stiffness (Elastography): 25%

  11. Slide 11: Zetomipzomib Treatment Demonstrates Alterations in Biomarker Activity Correlating With Biochemical Responses

    Zetomipzomib Treatment Demonstrates Alterations in Biomarker Activity Correlating With Clinically Relevant Biochemical Responses in AIH • Decreased B cell populations and increased CD56bright NK cell populations are detected • Elevated Tregs and reduced neutrophil-related proteins are observed in CR

  12. Slide 12: Favorable Safety and Tolerability Profile with Zetomipzomib Treatment

    Favorable Safety and Tolerability Profile with Zetomipzomib Treatment Safety Population (DBTP N=23; OLE N=14) Double-blind Treatment Period (DBTP) Open-label Extension (OLE) Adverse Events Placebo Zetomipzomib DBTP Placebo DBTP Zetomipzomib N=7 N=16 N=5 N=9 n (%) n (%) n (%) n (%) Participants with

  13. Slide 13: PORTOLA Marks First Successful Randomized Phase 2 Trial in Relapsed/Refractory AIH

    PORTOLA Marks First Successful Randomized Phase 2 Trial in Relapsed/Refractory AIH • Zetomipzomib demonstrates rapid, durable, and steroid-sparing disease modifying activity in a difficult-to-treat population of patients with AIH • Favorable safety and tolerability profile observed with zetomipzomib

  14. Slide 14: With deep appreciation to the patients, caregivers, investigators, and study site personnel

    With deep appreciation to the patients, caregivers, investigators, and study site personnel whose commitment made this study possible.

Kezar Life Sciences — Technical Presentation (November 2025) on 6ix